Pancreatic cancer is one of the most dangerous types of tumors and is often associated with early mortality. A genetic alteration known as the KRASG12D mutation makes treatment particularly challenging. A new drug called MRTX1133 has the potential to enhance the effectiveness of chemotherapy for this specific mutation. The research team plans to study pancreatic cancers with KRASG12D in more detail. Pancreatic cancer cells will be cultivated in the lab to test various treatment combinations with MRTX1133. Initial results indicate that tailored drug combinations are more effective. These findings could lead to new, individualized treatment strategies that significantly improve patient survival.

Here you can find further information.